Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is poised for success, as shown by their promising drug ZUNVEYL's positive differentiations and potential for increased market penetration, as well as the recent settlement to eliminate future obligations and strengthen the company's cash position. Utilizing a DCF-based valuation, Alpha Cognition's prospects suggest a total enterprise value of $500M, with a 12-month price objective of $18 per share, while potential risks include sales traction and competition challenges.

Bears say

Alpha Cognition is currently overvalued with a DCF-based valuation methodology calculating its worth at $520M, which is significantly lower than its current market capitalization. Additionally, risks include the company's dependence on its one product, ZUNVEYL, to drive revenue and potential delays in achieving sales traction for the drug. Despite a recent beat on financial results, the company is still operating at a loss and has a limited cash reserve, which may lead to dilution risk in the long-term.

ACOG has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACOG has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.